SEC Tracker
Get the app

Myriad Genetics MYGN

Myriad Genetics detected unauthorized access

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Unauthorized access detected on Nov 2, 2026
  2. Testing operations temporarily suspended
  3. Most systems back to normal
  4. No material adverse effect expected

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Myriad Genetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Kura Oncology KURA public float $496M, Jun 30, 2025
  2. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  3. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. aTYR PHARMA ATYR public float $464M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.